Donanemab
Treatment for Alzheimers Disease
Typical Dosage: 700 mg IV every 4 weeks for first 3 doses, then 1400 mg IV every 4 weeks
Effectiveness
57%
Safety Score
48%
Clinical Trials
10
Participants
3.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
700 mg IV every 4 weeks for first 3 doses, then 1400 mg IV every 4 weeks
Time to Effect
6-12 months
Treatment Duration
Until amyloid clearance (6-18 months), then monitoring
Evidence Quality
MODERATENumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
78%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$27,500
Monitoring:$8,000
Side Effect Mgmt:$2,500
Total Annual:$38,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$600,000/QALY
QALYs Gained
0.22
Comparison vs No treatment / symptomatic treatment
Cost Difference
+$38,000/year
More expensive
QALY Difference
+0.22 QALYs
Better outcomes
Dominance
No dominance
Donanemab Outcomes
for Alzheimers Disease
Efficacy Outcomes
Overall Effectiveness
+57%
Common Side Effects
ARIA-E (edema)
+24%
ARIA-H (hemorrhage)
+31%
Headache
+10%
Infusion-related reactions
+8.7%
Active Clinical Trials
7 active trials recruiting for Donanemab in Alzheimers Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
NCT06996730NOT YET RECRUITINGPHASE2, PHASE3
240 participants
INTERVENTIONAL
Medellín, Colombia
Started: Jan 15, 2026
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866ACTIVE NOT RECRUITINGPHASE3
3K participants
INTERVENTIONAL
Birmingham, United States +215 more
Started: Aug 27, 2021
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511ACTIVE NOT RECRUITINGPHASE3
1.74K participants
INTERVENTIONAL
Gilbert, United States +273 more
Started: Jun 19, 2020
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
NCT06566170RECRUITING
6.25K participants
OBSERVATIONAL
Huntsville, United States
Started: Oct 7, 2024
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
NCT06911944NOT YET RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Started: Aug 1, 2026
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789RECRUITINGPHASE3
1.5K participants
INTERVENTIONAL
ABB, Argentina +140 more
Started: Oct 10, 2022
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486ACTIVE NOT RECRUITINGPHASE3
1.18K participants
INTERVENTIONAL
Chandler, United States +48 more
Started: Feb 28, 2023
Completed Clinical Trials
3 completed trials for Donanemab in Alzheimers Disease
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
NCT03367403COMPLETEDPHASE2
272 participants
INTERVENTIONAL
Phoenix, United States +60 more
Started: Dec 18, 2017
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
NCT05108922COMPLETEDPHASE3
148 participants
INTERVENTIONAL
Fullerton, United States +30 more
Started: Nov 16, 2021
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
NCT04640077COMPLETEDPHASE2
95 participants
INTERVENTIONAL
Phoenix, United States +26 more
Started: Nov 23, 2020